Step into Tomorrow’s Radiotherapy
We’re leading the way with Vepoloxamer in head and neck cancer treatment.
Liferaft Biosciences utilizes Vepoloxamer’s therapeutic potential
during radiation therapy against severe oral mucositis to mitigate systemic oxidative injury.
The Problem: Only Symptomatic Relief
Many patients undergoing radiation therapy for cancer treatment experience debilitating side effects such as severe oral mucositis. This not only diminishes their quality of life but also poses challenges for healthcare providers in managing these symptoms effectively without delaying their treatment and cancer outcomes.
Traditional approaches to mitigating oral mucositis have been limited, often providing only symptomatic relief rather than addressing the underlying mechanisms driving tissue damage and inflammation.
There are currently no approved drugs by the U.S. Food and Drug Administration for severe oral mucositis in patients receiving radiotherapy for head and neck cancer.
The Potential: Protection & Wellness
Enter Vepoloxamer, a purified copolymer therapeutic agent with unique properties that make it ideally suited for combating the effects of radiation therapy-induced oral mucositis.
By scavenging free radicals, minimizing inflammation, and protecting cell membranes, Vepoloxamer offers the potential to mitigate patient recovery challenges posed by oral mucositis during radiation therapy.
Key opinion leaders at both the NIH-NCI and within industry say:
“All solid tumors could be cured with radiation therapy if we could protect the normal healthy tissue” and “There is currently no technology available that protects the healthy tissue from the side effects of radiation”
…Until Now
The Proof: Preclinical & Clinical Studies
Extensive preclinical and clinical studies have demonstrated the efficacy of Vepoloxamer in minimizing oral mucositis and promoting tissue repair in patients undergoing radiation therapy.
Velopoxamer inhibits the activation of inflammatory pathways, restores vascular function, and enhances cellular resilience to oxidative stress. Moreover, its safety profile and ease of administration make it a promising candidate for integration into standard of care radiation therapy protocols.
What Experts Are Saying
“One of the key features is that we discovered a physical chemistry phenomenon of pairing radicalized electrons that inhibited the propagation of an innated inflammatory injury. It is, however, the enabling discovery that makes Vepoloxamer work.”
-Michael J. Yost, PhD, FAIMBE
American Institute for Medical and Biological Engineering / Principal Investigator
The Patients: A Beacon of Hope
By alleviating the burden of oral mucositis and enabling patients to maintain better oral health and nutritional intake, Vepoloxamer empowers patients to navigate their cancer treatment journey with greater comfort and confidence.
With LifeRaft Biosciences at the forefront of innovation in cancer care, patients can look forward to a future where the adverse effects of radiation therapy are minimized, and the promise of improved treatment outcomes becomes a reality.
